Product
ISL
Aliases
MK-8591, Placebo to ISL
5 clinical trials
5 indications
Indication
HIV-1 InfectionIndication
Preexposure Prophylaxis for HIVIndication
HIV-IIndication
HIV-1Indication
ProphylaxisClinical trial
A Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVStatus: Active (not recruiting), Estimated PCD: 2023-12-19
Clinical trial
A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once-DailyStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISLStatus: Completed, Estimated PCD: 2022-11-21
Clinical trial
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Men and Transgender Women Who Have Sex With Men, and Are at High Risk for HIV-1 InfectionStatus: Completed, Estimated PCD: 2023-08-04
Clinical trial
A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for HIV-1 InfectionStatus: Active (not recruiting), Estimated PCD: 2023-07-18